Compare CTXR & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTXR | VNRX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 22.5M |
| IPO Year | 2010 | 2012 |
| Metric | CTXR | VNRX |
|---|---|---|
| Price | $0.65 | $2.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $6.00 | $1.67 |
| AVG Volume (30 Days) | 696.7K | ★ 3.0M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.38 | 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,727,384.00 |
| Revenue This Year | N/A | $355.66 |
| Revenue Next Year | $147.57 | $849.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 40.04 |
| 52 Week Low | $0.63 | $0.13 |
| 52 Week High | $2.38 | $0.94 |
| Indicator | CTXR | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.33 | 97.58 |
| Support Level | N/A | $0.20 |
| Resistance Level | $0.98 | N/A |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | -0.02 | 0.16 |
| Stochastic Oscillator | 5.97 | 97.77 |
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.